Biomarin Pharmaceutical Inc BMRN Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 16, 2023 (filed on Mar 17, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-3,973

Price:

$93.41
Mar 16, 2023 (filed on Mar 17, 2023)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-36,000

Price:

$93.41
Mar 16, 2023 (filed on Mar 17, 2023)

Insider Name:

Davis George Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-19,957

Price:

$93.41
Mar 16, 2023 (filed on Mar 17, 2023)

Insider Name:

Bienaime Jean Jacques

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-88,623

Price:

$93.41
Mar 16, 2023 (filed on Mar 17, 2023)

Insider Name:

Ajer Jeffrey Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-20,510

Price:

$93.41
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy Common Stock)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,320

Price:

--
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,856

Price:

$87.74
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,900

Price:

--
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy Common Stock)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

21,970

Price:

--
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,708

Price:

$87.74

Filings by filing date

Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy Common Stock)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,320

Price:

--
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,856

Price:

$87.74
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,900

Price:

--
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy Common Stock)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

21,970

Price:

--
Mar 16, 2023 (filed on Mar 17, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-3,973

Price:

$93.41
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,708

Price:

$87.74
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,630

Price:

--
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy Common Stock)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

38,450

Price:

--
Mar 16, 2023 (filed on Mar 17, 2023)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-36,000

Price:

$93.41
Mar 15, 2023 (filed on Mar 17, 2023)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,799

Price:

$87.74

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	105 Digital Dr NOVATO CA 94949-8703
Tel:	N/A
Website:	https://www.biomarin.com
IR:	See website

Key People

Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer	Brian R. Mueller Chief Financial Officer, Executive Vice President - Finance	Henry J. Fuchs President - Worldwide Research and Development
C. Greg Guyer Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer	G. Eric Davis Executive Vice President, General Counsel, Secretary	Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Humaira Serajuddin Senior Vice President, Chief Marketing Officer	Erin Burkhart Group Vice President, Chief Accounting Officer

Business Overview

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company's clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.

Financial Overview

For the fiscal year ended 31 December 2022, Biomarin Pharmaceutical Inc revenues increased 14% to $2.1B. Net income before extraordinary items totaled $141.6M vs. loss of $68M. Revenues reflect Voxzogo segment increase from $5.9M to $169.1M, Naglazyme1 segment increase of 17% to $443.8M, Europe segment increase of 16% to $651M, Latin America segment increase of 40% to $266.8M.

Employees:	3,082 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$16,850M as of Dec 31, 2022
Annual revenue (TTM):	$2,096M as of Dec 31, 2022
EBITDA (TTM):	$143.53M as of Dec 31, 2022
Net annual income (TTM):	$141.56M as of Dec 31, 2022
Free cash flow (TTM):	$44.36M as of Dec 31, 2022
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	186,528,784 as of Feb 16, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization